Know What's Happening in BioTech
Know What's Happening in BioTech
BioTech Pulse
EMAIL DIGESTS
Daily
Every morning
Weekly
Tuesday recap
EMAIL DIGESTS
Daily
Every morning
Weekly
Tuesday recap
The article outlines BioCentury’s cookie policy, detailing categories of cookies used on its website. Strictly necessary cookies are always active and enable authentication, registration, and core navigation. Functional, marketing, advertising, and analytics cookies provide personalization, targeted promotions, ad tracking, and performance insights, respectively. The policy emphasizes that none of these cookies store personally identifiable information, though they collect aggregate usage data.
A Phase I/II trial of AMT‑130, an AAV‑delivered microRNA gene therapy, showed a 75% reduction in Huntington's disease progression over three years in 12 patients. The FDA initially supported using external control data from the Enroll‑HD database for the Biologics...
The blog by HotSpot Therapeutics CEO Jonathan Montagu argues that China is no longer just a manufacturing hub but a burgeoning source of innovative drug candidates, evidenced by its 17% lead over the U.S. in Nature’s Index and nearly half...
Researchers have discovered that microglia, the brain’s innate immune cells, can actively remodel soluble amyloid‑β (Aβ42) into extracellular fibrils with strong seeding activity, contrary to the prevailing view that they only clear plaques. Cell‑based assays showed that microglia‑generated amyloid closely...
GEN Pharmaceuticals received BEBO Foundation ethical approval to launch a Phase II proof‑of‑concept trial of its mitochondrial‑targeting drug SUL‑238 in Parkinson’s disease. The single‑centre, randomised, double‑blind, placebo‑controlled study, named SHEPHERD, will begin patient enrolment in Groningen in April 2026. Over a 28‑day...
Engineered lipid nanoparticles with modified ionizable lipids enhance immune cell metabolism, improve mRNA vaccine delivery to lymph nodes, and reduce inflammatory side effects in preclinical models. vaccinetechnology
R1 starts up with $78M, aiming for a better kidney drug https://t.co/PQQjX47ODM by @gwendolynawu #biotecjh #startups
NeuroScientific Biopharmaceuticals has begun its first manufacturing run of the StemSmart mesenchymal stem cell therapy at Q‑Gen Cell Therapeutics in Brisbane, initiating a critical technology transfer. The engineering run will validate quality, potency and regulatory compliance ahead of a Phase 2...
Sleeping sickness could be wiped out with this new drug: my comments @NPR @NPRGlobalHealth https://t.co/T0mAeX8P0A
It’s time for the annual vote for best engineered yeast bioart from the @ImperialBioeng undergrad #SynBio students. Help us decide among these beautiful final 4 with your votes. 🗳️ ⬇️ https://t.co/2fo1XaGCmL
Abeona Therapeutics reported its Q4 2018 results, highlighting progress on its lead cell therapy EB-101 for recessive dystrophic epidermolysis bullosa (RDEB). The Phase 1/2 trial demonstrated continuous type VII collagen expression for over two years, a favorable safety profile, and durable wound...
Cibus reported a $9.9 million cash balance and a $22.3 million capital raise that extends its runway into late 2026. Operating expenses were trimmed by roughly $10 million, though the quarter posted a $31.9 million net loss. The company highlighted a $200 million royalty opportunity...
Ionis Pharmaceuticals announced that its Phase 1/2a PrProfile trial of ION717, the first PrP‑lowering antisense oligonucleotide for symptomatic prion disease, has reopened with a third dosing regimen. The study, which enrolled 56 patients in 2024, will now recruit at three...
Researchers at the University of Colorado Boulder have created a light‑controlled hydrogel that closely replicates the softness and viscoelastic behavior of human tissue. The material can be solidified or softened on demand using photopolymerization, allowing precise spatial control during 3‑D...
The FDA has approved updated labeling for all pioglitazone‑containing medicines, adding a warning that use longer than one year may increase bladder cancer risk. Healthcare professionals are instructed not to prescribe pioglitazone to patients with active bladder cancer and to...
The FDA has approved label changes for general anesthetic and sedation drugs used in children under three, adding a warning that prolonged exposure—more than three hours or multiple procedures—may harm brain development. The revisions incorporate animal study data showing neuronal...
Researchers at the Wyss Institute have created the first “neurobots,” living robots built from frog embryonic cells that incorporate neuronal precursor cells to form self‑organizing nervous systems. The neurobots develop mature neurons that connect internally and extend processes to surface...
A joint effort by EMBL‑EBI, Google DeepMind, NVIDIA and Seoul National University has added millions of AI‑predicted protein complex structures to the AlphaFold Database, marking the largest collection of such data to date. The release focuses on high‑confidence homodimers, delivering...
Integrated DNA Technologies (IDT) announced a new next‑generation sequencing (NGS) portfolio that includes the DNA EZ v2 library preparation kit, the xGen Exome v2 Hyb spike‑in panel, a 1,536‑member set of full‑length unique dual‑index adapters, and an upgraded whole‑genome sequencing system. The suite targets...
Illumina unveiled Illumina Connected Multiomics, a cloud‑based platform that unifies single‑cell, spatial transcriptomics, proteomics, and methylation data for large‑scale analysis. The system aggregates thousands of samples from Illumina and third‑party assays, delivering reproducible results through DRAGEN secondary analysis. AI‑driven tools...
Cepheid’s Xpert GI panel received FDA clearance, offering a multiplex PCR test that identifies 11 bacterial, viral, and parasitic gastrointestinal pathogens from a single stool sample. The assay delivers results in roughly 74 minutes and operates on the existing GeneXpert...
The U.S. Food and Drug Administration granted 510(k) clearance to Copan Group’s PhenoMatrix, an AI‑driven image‑assessment tool that runs on the WASPLab automation platform. Classified as a class II device, the software automatically sorts and evaluates bacterial culture plate images across...
Scientists have engineered silica‑based nanoparticles that encapsulate rifampicin and release it only when exposed to low‑frequency ultrasound. The ultrasound both propels the particles through the protective matrix of bacterial biofilms and triggers cavitation that opens the particles, delivering the antibiotic...
Artificial intelligence is reshaping genomics by speeding up sequencing and uncovering patterns that traditional tools miss, enabling truly personalized medicine. AI models can predict disease risk, suggest optimal therapies, and guide tumor classification, especially in oncology and emerging mRNA vaccine...
Researchers have mapped how senescence spreads between human brain cell types via the senescence‑associated secretory phenotype (SASP). Using DNA‑damage‑induced cultures and conditioned‑media assays, they identified cell‑type‑specific SASP signatures that drive secondary senescence in neighboring astrocytes, endothelial cells, microglia, oligodendrocytes and...
Synergy Spine Solutions secured FDA pre‑market approval for its Synergy Disc, the first artificial cervical disc that simultaneously improves spinal alignment and preserves full range of motion. The device features a patented interrupted‑articulation geometry that creates a low‑energy, lordotic position...
NovaBridge’s VIS‑101, a dual VEGF‑A and angiopoietin‑2 inhibitor, delivered rapid and durable efficacy in a phase 2a trial of 38 wet AMD patients in China. Participants receiving 3 mg or 6 mg doses achieved mean visual gains exceeding 10 ETDRS letters and central...
Structure Therapeutics announced positive topline data from its ACCESS II trial of aleniglipron, an oral small‑molecule GLP‑1 receptor agonist. The study demonstrated statistically significant reductions in HbA1c and weight loss comparable to injectable GLP‑1 therapies. Safety signals were mild, with few...
CytomX Therapeutics’ shares surged 66% after the company released expansion data from its Phase 1 study of Varseta‑M, a masked antibody‑drug conjugate targeting EpCAM in late‑stage colorectal cancer. The trial evaluated three dose levels, with the two highest doses achieving response...
Sun Pharmaceutical's tildrakizumab (Ilumya) received FDA acceptance for a supplemental biologics license application to treat active psoriatic arthritis. The sBLA is backed by two Phase III INSPIRE studies involving more than 800 patients, which met primary endpoints with significant ACR20 improvements...
Chinese-owned agriscience leader Syngenta announced a £100 million investment to build a new bioscience hub, BioSTaR, at its Jealott’s Hill site in Berkshire. The centre will consolidate 300 scientists to develop biological pesticides and AI‑enabled crop protection technologies, with completion targeted...
Researchers have identified that a surface‑defensive molecule on cancer cells not only sends a “don’t‑eat‑me” signal but also conceals an “eat‑me” cue that would normally trigger immune clearance. A newly engineered antibody can disrupt this masking interaction, making tumors visible...
Qlaris Bio announced that Fred Guerard, PharmD, will serve as its president and chief executive officer, succeeding co‑founder Thurein Htoo. The biotech is moving its lead candidate, QLS‑111, into Phase 3 trials for open‑angle glaucoma and ocular hypertension. Guerard arrives with...
A retrospective TriNetX analysis of 1,691 psoriasis patients compared bimekizumab with IL‑23 inhibitors and found no greater incidence of new‑onset depression, suicidal ideation, or related medication use. Over a two‑year follow‑up, the combined psychiatric event rate was 4.9% for bimekizumab...
Researchers at Sanford Burnham Prebys unveiled TLPath, a machine‑learning model that infers telomere length from routine histopathology slides. The system was trained on 5,263 whole‑slide images covering 18 organs from 919 individuals and can predict telomere shortening in 11 tissue...
Actually yes. The placenta has been used in medicine for over 100 years. The amniotic membrane is used in eye surgery for corneal reconstruction. It's used as a graft for burn treatment and wound healing. It's used in dental and orthopedic...
Will ask colleagues to respond because I haven’t been tracking all the tickers. Pls reply with examples of biotech trade press being called too negative
NeoGenomics announced that its PanTracer™ LBx liquid biopsy test has received Medicare coverage under CMS’s MolDX program. The CLIA‑certified assay profiles more than 500 genes, including MSI and blood‑tumor mutational burden, with a seven‑day turnaround. Coverage allows Medicare beneficiaries to...
Researchers at Cardiff University found that severe DNA mutations called chromoanasynthesis happen when broken chromosomes are repaired using small DNA fragments, causing chaotic duplications that can drive cancer and genetic diseases. 🧬https://t.co/Q9j2hRezTs
Kennedy childhood vaccine overhaul stalled by judge The next meeting of the Advisory Committee on Immunization Practices was scheduled for this week, but has been postponed due to the ruling https://t.co/0cUIXEVgyV
Sentynl Therapeutics, a Zydus Lifesciences subsidiary, has licensed Progerinin, an oral small‑molecule candidate for Hutchinson‑Gilford Progeria Syndrome, from PRG S&T. The agreement grants Sentynl full development rights, making Progerinin its second HGPS therapy and giving it orphan‑drug status from the FDA....
A study in Alzheimer's & Dementia found that late-life methionine restriction reduces Alzheimer’s pathology and neuroinflammation in mice by activating the liver–brain FGF21–FGFR1 signaling pathway, independent of metabolic improvements. 🧠 https://t.co/A9kEqNv8pO
Beyond the Weight Loss: The Effects of Semaglutide on Standard and Diet-Induced Obese Mice 🤔"..semaglutide improved glucose metabolic health inboth diet groups..while chronic semaglutide treatment appeared to exertanxiolytic effects in obese mice, opposit[e] effects were observed in lean animals.." https://t.co/doU6EkwT7z
Six biotech firms are pushing next‑generation prostate‑cancer therapies through late‑stage trials and financing milestones. Candel Therapeutics secured a $100 million royalty deal to fund aglatimagene’s launch, while Coherus Oncology closed a $50.1 million offering and partnered with J&J for a CCR8 antibody...
FDA commissioner Makary at a CMS conference today in Baltimore calls for “big and different” IRB reforms to catch China's speedy trial starts - pre-IND phase can run 380 days in the US, he said, while China is pushing for...
CytomX surges on positive data for ‘masked’ ADC in colorectal cancer https://t.co/PxQMISvyri by @Lilah_Alvarado $CTMX + 66%
Structure’s GLP-1 pill shows ‘best-in-class’ potential in obesity trial https://t.co/j0fzAg6GRV @ByJonGardner $GPCR $LLY $NVO $AZN $MRK #obesity
A polygenic risk score that predicts Type 2 diabetes, obesity, and likelihood for requiring a GLP-1 drug. Across 6 ancestries. https://t.co/5hTVv8kqlK https://t.co/IgXhx8vFA6
16March: Which companies recently withdrew their planned IPOs? And how much have the stocks of this year's #biotech IPOs risen or fallen this year? Read about the IPO market plus updates on $BNTX, $IXHL, and $INKT in my latest StockWatch...
The era of digital biology, exemplified by making a bespoke and effective vaccine for cancer in a dog, is taking off. Access to the AI-Coscientist. A new feature @NatureMedicine https://t.co/AR9lqne7E1
